Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
991 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia(ALLight) | recruiting | Phase 1 / Phase 2 | 83 | AstraZenecaINDUSTRY | 9 | Jul 13, 2026 | clinicaltrials |
| NCT04482309 | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors(DPT02) | active not recruiting | Phase 2 | 477 | AstraZenecaINDUSTRY | 17 | Jul 10, 2026 |
| clinicaltrials |
| NCT04830709 | Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer(SCOUT-1) | active not recruiting | — | 752 | AstraZenecaINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05048797 | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | active not recruiting | Phase 3 | 454 | AstraZenecaINDUSTRY | 20 | Jul 10, 2026 | clinicaltrials |
| NCT06109779 | Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | active not recruiting | Phase 3 | 760 | AstraZenecaINDUSTRY | 21 | Jul 10, 2026 | clinicaltrials |
| NCT05629234 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)(ROSY-T) | active not recruiting | Phase 3 | 37 | AstraZenecaINDUSTRY | 8 | Jul 9, 2026 | clinicaltrials |
| NCT06346392 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | active not recruiting | Phase 3 | 594 | AstraZenecaINDUSTRY | 19 | Jul 9, 2026 | clinicaltrials |
| NCT04560452 | Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients | completed | — | 1,018 | AstraZenecaINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05891847 | Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia | terminated | — | 150 | AstraZenecaINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06386263 | HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada(HER-TEMPO) | completed | — | 22 | AstraZenecaINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03528694 | Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer(POTOMAC) | active not recruiting | Phase 3 | 1,018 | AstraZenecaINDUSTRY | 12 | Jul 7, 2026 | clinicaltrials |
| NCT03737643 | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients(DUO-O) | active not recruiting | Phase 3 | 1,407 | AstraZenecaINDUSTRY | 20 | Jul 7, 2026 | clinicaltrials |
| NCT04765059 | A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)(COMPEL) | active not recruiting | Phase 3 | 98 | AstraZenecaINDUSTRY | 6 | Jul 7, 2026 | clinicaltrials |
| NCT06147037 | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | active not recruiting | Phase 1 | 13 | AstraZenecaINDUSTRY | 2 | Jul 7, 2026 | clinicaltrials |
| NCT04745689 | Study of AZD2811 + Durvalumab in ES-SCLC(TAZMAN) | active not recruiting | Phase 2 | 31 | AstraZenecaINDUSTRY | 4 | Jul 6, 2026 | clinicaltrials |
| NCT05120349 | A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection(ADAURA2) | active not recruiting | Phase 3 | 390 | AstraZenecaINDUSTRY | 20 | Jul 6, 2026 | clinicaltrials |
| NCT06764186 | A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain(CAPItana) | active not recruiting | Phase 3 | 101 | AstraZenecaINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03330847 | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | active not recruiting | Phase 2 | 273 | AstraZenecaINDUSTRY | 15 | Jul 2, 2026 | clinicaltrials |
| NCT06179511 | Study of AZD9829 in CD123+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 56 | AstraZenecaINDUSTRY | 10 | Jul 1, 2026 | clinicaltrials |
| NCT07098338 | A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)(LIBRA) | recruiting | Phase 2 | 278 | AstraZenecaINDUSTRY | 12 | Jul 1, 2026 | clinicaltrials |
| NCT05938270 | A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.(ASCERTAIN) | completed | Phase 1 | 113 | AstraZenecaINDUSTRY | 6 | Jun 30, 2026 | clinicaltrials |
| NCT03198650 | A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies | completed | Phase 1 | 35 | AstraZenecaINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07674121 | PROLONG (PRostateOLaparibONcombinationGcc) Study(PROLONG) | not yet recruiting | — | 75 | AstraZenecaINDUSTRY | 0 | Jun 29, 2026 | clinicaltrials |
| NCT05557838 | Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC(TREMENDOUS) | active not recruiting | Phase 3 | 214 | AstraZenecaINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07146113 | Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation(PRIME) | suspended | — | 400 | AstraZenecaINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07154901 | Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373) | completed | Phase 1 | 35 | AstraZenecaINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06713369 | AZD5305 hADME in Patients With Advanced Solid Malignancies(AZD5305) | recruiting | Phase 1 | 8 | AstraZenecaINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06890273 | NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)(DUOLife) | recruiting | — | 150 | AstraZenecaINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06676436 | Observational Study on the Treatment of Patients With Metastatic Breast Cancer(REALNESS) | completed | — | 204 | AstraZenecaINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05221840 | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer(PACIFIC-9) | active not recruiting | Phase 3 | 1,051 | AstraZenecaINDUSTRY | 20 | Jun 18, 2026 | clinicaltrials |
| NCT07215585 | AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL(SOUNDTRACK-D2) | recruiting | Phase 3 | 420 | AstraZenecaINDUSTRY | 11 | Jun 18, 2026 | clinicaltrials |
| NCT07143604 | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2(GAMBIT) | active not recruiting | Phase 2 | 33 | AstraZenecaINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05683977 | A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.(ARSENAL) | active not recruiting | — | 254 | AstraZenecaINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06767462 | An Ophthalmic Safety Study in Patients With Breast Cancer | active not recruiting | — | 160 | AstraZenecaINDUSTRY | 11 | Jun 16, 2026 | clinicaltrials |
| NCT05629585 | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | active not recruiting | Phase 3 | 1,174 | AstraZenecaINDUSTRY | 17 | Jun 15, 2026 | clinicaltrials |
| NCT06245837 | Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations | active not recruiting | — | 1,500 | AstraZenecaINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04421963 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib(ROSY-O) | active not recruiting | Phase 3 | 185 | AstraZenecaINDUSTRY | 23 | Jun 12, 2026 | clinicaltrials |
| NCT07643870 | Human ADME Study of [14C]-AZD1390 | not yet recruiting | Phase 1 | 8 | AstraZenecaINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03003962 | Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | active not recruiting | Phase 3 | 669 | AstraZenecaINDUSTRY | 12 | Jun 11, 2026 | clinicaltrials |
| NCT04960709 | Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin(VOLGA) | active not recruiting | Phase 3 | 712 | AstraZenecaINDUSTRY | 25 | Jun 4, 2026 | clinicaltrials |
| NCT07213076 | Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib. | completed | — | 350 | AstraZenecaINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06842056 | Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records(DIASTAG) | not yet recruiting | — | 3,000 | AstraZenecaINDUSTRY | 0 | Jun 2, 2026 | clinicaltrials |
| NCT05667064 | Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study | completed | — | 1,200 | AstraZenecaINDUSTRY | 0 | Jun 1, 2026 | clinicaltrials |
| NCT05918042 | A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation(OVARD) | completed | — | 414 | AstraZenecaINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT00600496 | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | completed | Phase 1 | 140 | AstraZenecaINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT05887011 | CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia(PASSAT) | active not recruiting | — | 2,000 | AstraZenecaINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT05043090 | Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC(SAMETA) | active not recruiting | Phase 3 | 148 | AstraZenecaINDUSTRY | 25 | May 22, 2026 | clinicaltrials |
| NCT07593196 | HER2-positive Metastatic Breast Cancer in Kazakhstan | not yet recruiting | — | 240 | AstraZenecaINDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT05374512 | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) | active not recruiting | Phase 3 | 644 | AstraZenecaINDUSTRY | 23 | May 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials